Novartis shares drop after cholesterol drug study failure
Novartis shares fell 3.3% Monday morning after its cholesterol drug pelacarsen failed in a closely watched study, increasing pressure on its pipeline and casting new doubt on the approach.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.